Business
Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA. The DDR In
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA.","length":494,"tagName":"p"},{"type":"text","content":"The DDR Inhibitors Summit is recognized as a premier global forum uniting translational scientists, clinicians, and biotechnology innovators working to advance next-generation DDR-targeted cancer therapies. The 2026 program will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, with a strong focus on translational strategies to accelerate clinical impact.","length":419,"tagName":"p"},{"type":"text","content":"Prof. Daugaard will deliver a featured presentation titled: “Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics”","length":145,"tagName":"p"},{"type":"text","content":"His session will highlight Rakovina’s pivot to an AI-enabled drug discovery model and showcase studies of AI-designed DDR programs progressing through preclinical lead selection and toward development.","length":201,"tagName":"p"},{"type":"text","content":"In addition to his presentation, Prof. Daugaard will participate in a fireside chat entitled “Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures” and a panel discussion on “Uniting Founders and Funders to Align Scientific Vision with Investment Strategy.” In these sessions, he will join a distinguishe...